{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:26:48Z","timestamp":1792445208089,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jconrel.2021.08.050","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:04:07Z","timestamp":1630461847000},"page":"358-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction"],"prefix":"10.1016","volume":"338","author":[{"given":"Jinhui","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiran A.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Nesbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridgeen","family":"Callan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McKaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"McHale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Callan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.08.050_bb0005","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2021.08.050_bb0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11912-012-0290-4","article-title":"The role of the FOLFIRINOX regimen for advanced pancreatic cancer","volume":"15","author":"Conroy","year":"2013","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.jconrel.2021.08.050_bb0015","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdh470","article-title":"First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil\/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule","volume":"15","author":"Masi","year":"2004","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2021.08.050_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2050-5736-1-10","article-title":"Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors","volume":"1","author":"Chen","year":"2013","journal-title":"J. Therap. Ultrasound."},{"key":"10.1016\/j.jconrel.2021.08.050_bb0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-7020-3131-1.00006-7","article-title":"Ultrasonic contrast agents","author":"Moran","year":"2011","journal-title":"Clin. Ultrasound."},{"issue":"1","key":"10.1016\/j.jconrel.2021.08.050_bb0030","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1109\/TUFFC.2006.1588398","article-title":"Ultrasonic contrast agent shell rupture detected by inertial cavitation and rebound signals","volume":"53","author":"Ammi","year":"2006","journal-title":"IEEE Trans. Ultrason. Ferroelectr. Freq. Control"},{"issue":"1","key":"10.1016\/j.jconrel.2021.08.050_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40336-014-0052-4","article-title":"Ultrasound and microbubbles for treatment purposes: mechanisms and results","volume":"2","author":"Tranquart","year":"2014","journal-title":"Clin. Trans. Imag."},{"issue":"4","key":"10.1016\/j.jconrel.2021.08.050_bb0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4155\/tde.14.10","article-title":"Mechanisms of microbubble-facilitated sonoporation for drug and gene delivery","volume":"5","author":"Fan","year":"2014","journal-title":"Ther. Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2021.08.050_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nphys148","article-title":"Membrane disruption by optically controlled microbubble cavitation","volume":"1","author":"Prentice","year":"2005","journal-title":"Nat. Phys."},{"key":"10.1016\/j.jconrel.2021.08.050_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejpb.2020.10.012","article-title":"An ultrasound responsive microbubble-liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic cancer","volume":"157","author":"Gao","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.08.050_bb0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejpb.2019.04.003","article-title":"Targeted chemo-sonodynamic therapy treatment of breast tumours using ultrasound responsive microbubbles loaded with paclitaxel, doxorubicin and rose Bengal","volume":"139","author":"Logan","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.08.050_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2018.04.018","article-title":"Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer","volume":"279","author":"Nesbitt","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.050_bb0065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2016.10.007","article-title":"A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer","volume":"243","author":"Dimcevski","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.050_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.biomaterials.2015.11.033","article-title":"Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle","volume":"80","author":"McEwan","year":"2016","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2021.08.050_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2015.02.004","article-title":"Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours","volume":"203","author":"McEwan","year":"2015","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2021.08.050_bb0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7150\/ntno.37738","article-title":"Phospholipid prodrug conjugates of insoluble chemotherapeutic agents for ultrasound targeted drug delivery","volume":"4","author":"M\u00e1rquez","year":"2020","journal-title":"Nanotheranostics."},{"issue":"5","key":"10.1016\/j.jconrel.2021.08.050_bb0085","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/02713689309024621","article-title":"A comparison of 5-Fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring","volume":"12","author":"Ward","year":"1993","journal-title":"Curr. Eye Res."},{"issue":"2","key":"10.1016\/j.jconrel.2021.08.050_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0040-4039(00)95685-5","article-title":"A facile one-step synthesis of 5\u2032-phosphatidylnucleosides by an enzymatic two-phase reaction","volume":"28","author":"Shuto","year":"1987","journal-title":"Tetrahedron Lett."},{"issue":"8","key":"10.1016\/j.jconrel.2021.08.050_bb0095","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"35","key":"10.1016\/j.jconrel.2021.08.050_bb0100","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"Wheate","year":"2010","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jconrel.2021.08.050_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jinorgbio.2018.11.008","article-title":"Multi-action Pt(IV) anticancer agents; do we understand how they work?","volume":"191","author":"Gibson","year":"2019","journal-title":"J. Inorg. Biochem."},{"issue":"26","key":"10.1016\/j.jconrel.2021.08.050_bb0110","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1039\/c4dt00911h","article-title":"Pros and cons of bifunctional platinum(iv) antitumor prodrugs: two are (not always) better than one","volume":"43","author":"Gabano","year":"2014","journal-title":"Dalton Trans."},{"issue":"1","key":"10.1016\/j.jconrel.2021.08.050_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jinorgbio.2011.10.012","article-title":"Pt(IV) complexes as prodrugs for cisplatin","volume":"107","author":"Shi","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jconrel.2021.08.050_bb0120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jinorgbio.2012.06.013","article-title":"What do we know about the reduction of Pt(IV) pro-drugs?","volume":"117","author":"Wexselblatt","year":"2012","journal-title":"J. Inorg. Biochem."},{"issue":"5","key":"10.1016\/j.jconrel.2021.08.050_bb0125","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) Prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2021.08.050_bb0130","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1021\/cr4004314","article-title":"Synthetic methods for the preparation of platinum anticancer complexes","volume":"114","author":"Wilson","year":"2013","journal-title":"Chem. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2021.08.050_bb0135","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1029698","article-title":"Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma","volume":"4","author":"Duewell","year":"2015","journal-title":"OncoImmunology."},{"issue":"5","key":"10.1016\/j.jconrel.2021.08.050_bb0140","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0360-3016(84)90301-8","article-title":"Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data","volume":"10","author":"Moulder","year":"1984","journal-title":"Int. J. Rad. Oncol. Biol. Phys."},{"issue":"14","key":"10.1016\/j.jconrel.2021.08.050_bb0145","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-18-0491","article-title":"Metabolic and physiologic imaging biomarkers of the tumor microenvironment predict treatment outcome with radiation or a hypoxia-activated prodrug in mice","volume":"78","author":"Matsumoto","year":"2018","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2021.08.050_bb0150","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot087163","article-title":"Measuring cell death by propidium iodide uptake and flow cytometry","volume":"2016","author":"Crowley","year":"2016","journal-title":"Cold Spring Harb Protoc"},{"issue":"7","key":"10.1016\/j.jconrel.2021.08.050_bb0155","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034793","article-title":"Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy","volume":"11","author":"Erstad","year":"2018","journal-title":"Dis. Model. Mech."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:05:47Z","timestamp":1759161947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921004648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":31,"alternative-id":["S0168365921004648"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.050","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}